Medicinski vjesnik, Vol. 37 No. (1-4), 2005.
Stručni rad
Immunotherapy of kidney cancer
Antonio Juretić
Nera Šarić
Vesna Bišof
Martina Bašić-Koretić,
Tvrtko Hudolin
Sažetak
Renal cell carcinoma (RCC) is generally resistant to standard chemotherapy, hormonal or irradiation treatments. Therefore, various drugs or therapies with immunomodulatory action were or are tested in kidney cancer patients. In clinical praxis many approaches have been investigated of which interferon-alpha (INF-") and interleukin-2 (IL-2) are the most extensively studied ones. These two cytokines can achieve response rates in 10% to 30% of patients with metastatic RCC. Long-term survival, however, is achieved only in few patients. More frequently in the ones who have been receiving high-dose IL-2. Consequently, the treatment of RCC is far from being optimal. Therefore, other and novel immunotherapeutic strategies are ongoing or planned to be tested in clinical trials.
Ključne riječi
Cytokines; Immunotherapy; Interferon-alpha, Interleukin-2; Metastatic; Renal cell carcinoma; Targeted therapy; Treatment
Hrčak ID:
190872
URI
Datum izdavanja:
1.12.2005.
Posjeta: 1.987 *